Taiwan COVID vaccine maker to apply for EUA after promising Phase II trial results

Medigen Vaccine Biologics Corp., a Taiwan-based biopharmaceutical company, said Thursday that it would seek an Emergency Use Authorization (EUA) for its COVID-19 vaccine candidate after unblinding the results of its Phase II clinical trials.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)